GeneDx 10-Q: Q3 Net Loss Widens to $12.3M, Nine-Month Operating Cash Burn Hits $72M
WGS sits 83% above its 52-week low of $32.21 on elevated volume (2.3× avg).
Summary
GeneDx's Q3 10-Q shows revenue up 5% to $123.1 million but a $12.3 million quarterly net loss and $72.0 million of nine-month operating cash burn, offset by $170.1 million of liquidity and a $150.0 million Blackstone term loan with a $75.0 million minimum liquidity covenant.
Key Events · Earnings and Guidance · WGS
-
Q3 Revenue Up 5%, Loss Widens
Total revenue rose to $123.1 million from $116.7 million, but net loss widened to $12.3 million from $7.6 million a year ago.
-
Nine-Month Cash Burn of $72M
Operating activities used $72.0 million in the nine months ended September 30, 2026, versus $36.4 million provided a year ago, on a $93.4 million net loss that includes a $31.3 million non-cash impairment.
-
$170M Liquidity, $150M Blackstone Loan
Cash and marketable securities totaled $170.1 million at quarter-end; the Blackstone term loan was upsized to $150.0 million aggregate principal and now requires minimum liquidity of $75.0 million.
-
New Securities Suits Over Fabric Deal
Putative class actions Basma (June 4, 2026) and Kanungo (July 28, 2026) allege misleading statements about the Fabric Genomics acquisition's impact; loss cannot be estimated.
Analysis · WGS · Industrial Applications And Services
The headline revenue number was already out, but the full 10-Q reveals the cost of growth: nine-month operating cash use of $72.0 million versus $36.4 million generated a year ago, driven by a $93.4 million net loss that includes a $31.3 million non-cash Fabric Genomics impairment and a $6.6 million debt-extinguishment charge. Against that, GeneDx holds $170.1 million of cash and marketable securities and has upsized its Blackstone term loan to $150.0 million, but that loan now carries a $75.0 million minimum liquidity covenant — a real constraint if the burn continues. Two new securities class actions over the Fabric Genomics acquisition and a fresh PAMA disclosure that CMS preliminary medians point to reimbursement cuts starting January 1, 2027 add overhangs the press release did not cover.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, WGS was trading at $59.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2B. The 52-week trading range was $32.21 to $170.87. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.